Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Jun 15, 2021; 13(6): 600-611
Published online Jun 15, 2021. doi: 10.4251/wjgo.v13.i6.600
Published online Jun 15, 2021. doi: 10.4251/wjgo.v13.i6.600
Table 1 Demographic and clinical characteristics of the three study groups
| HCC group | Cirrhosis group | Control group | P value | ||
| Gender | Male | 30 | 17 | 20 | > 0.05 |
| Female | 10 | 13 | 10 | ||
| Age (years) | mean (SD) | 60.07 ± 5.34 | 58.33 ± 8.07 | 55.2 ± 7.6 | > 0.05 |
| Range | 50-68 | 37-67 | 34-62 | ||
| Child-Pugh score, n (%) | A | 24 (60.0) | 19 (63.3) | Not applicable | |
| B | 11 (27.5) | 8 (26.7) | Not applicable | ||
| C | 5 (12.5) | 3 (10.0) | Not applicable |
- Citation: Alzamzamy A, Elsayed H, Abd Elraouf M, Eltoukhy H, Megahed T, Aboubakr A. Serum vascular endothelial growth factor as a tumor marker for hepatocellular carcinoma in hepatitis C virus-related cirrhotic patients. World J Gastrointest Oncol 2021; 13(6): 600-611
- URL: https://www.wjgnet.com/1948-5204/full/v13/i6/600.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i6.600